Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Sponsor: Jazz Pharmaceuticals
Terminated
Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual.
Other terminated trials from Jazz Pharmaceuticals
Other Acute Lung Injury trials with similar outcome
This PHASE2/PHASE3 trial investigates Acute Lung Injury and Coronavirus Disease 2019 (COVID-19) and is currently terminated or withdrawn. Jazz Pharmaceuticals leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Nov 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2021 — Sep 2022 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
▶ Show 7 earlier versions
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jazz Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .